more

McKesson (MCK)

(Real Time Quote from BATS)

$558.37 USD

+2.22 (0.40%)

Updated Aug 30, 2024 01:50 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	23.68%
2	Buy	17.55%
3	Hold	9.21%
4	Sell	4.93%
5	Strong Sell	2.36%
S&P	500	10.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

Bottom 26% (185 out of 251)

Industry: Medical - Dental Supplies

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Here's Why You Should Retain McKesson (MCK) Stock Right Now

by Zacks Equity Research Published on July 07,2021

McKesson (MCK) continues to benefit from its robust Distribution Solutions segment.

medical

Should Value Investors Buy McKesson (MCK) Stock?

by Zacks Equity Research Published on June 30,2021

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

MCKPositive Net Change

Is Xtrackers Russell US Multifactor ETF (DEUS) a Strong ETF Right Now?

by Zacks Equity Research Published on June 30,2021

Smart Beta ETF report for DEUS

Should SPDR Russell 1000 Momentum Focus ETF (ONEO) Be on Your Investing Radar?

by Zacks Equity Research Published on June 21,2021

Style Box ETF report for ONEO

Here's Why You Should Retain McKesson (MCK) Stock Right Now

by Zacks Equity Research Published on June 07,2021

McKesson (MCK) continues to benefit from its robust Distribution Solutions segment.

medical

Should Xtrackers Russell US Multifactor ETF (DEUS) Be on Your Investing Radar?

by Zacks Equity Research Published on June 07,2021

Style Box ETF report for DEUS

Strength Seen in McKesson (MCK): Can Its 6.8% Jump Turn into More Strength?

by Zacks Equity Research Published on May 10,2021

McKesson (MCK) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

MCKPositive Net Change

McKesson (MCK) Q4 Earnings Beat Estimates, Revenues Miss

by Zacks Equity Research Published on May 07,2021

McKesson's (MCK) fiscal fourth-quarter 2021 results benefit from strong performance at Medical-Surgical Solutions segment.

McKesson (MCK) Q4 Earnings Top Estimates

by Zacks Equity Research Published on May 06,2021

McKesson (MCK) delivered earnings and revenue surprises of 0.60% and -2.91%, respectively, for the quarter ended March 2021. Do the numbers hold clues to what lies ahead for the stock?

MCKPositive Net Change

Should You Buy McKesson (MCK) Ahead of Earnings?

by Zacks Equity Research Published on May 05,2021

McKesson (MCK) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.

MCKPositive Net Change

McKesson (MCK) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research Published on April 30,2021

McKesson's (MCK) fiscal fourth-quarter results are likely to reflect solid show by U.S. Pharmaceutical and Specialty Solutions segment.

medical

AmerisourceBergen (ABC) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research Published on April 30,2021

AmerisourceBergen's (ABC) fiscal second-quarter results are likely to reflect solid performance at Pharmaceutical Distribution and Other units.

medical

Invitae (NVTA) to Report Q1 Earnings: What's in the Offing?

by Zacks Equity Research Published on April 29,2021

Invitae's (NVTA) first-quarter results are likely to reflect strength in genetic testing.

medical

Why Investors Need to Take Advantage of the Zacks ESP Screener

by Zacks Equity Research Published on April 28,2021

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

MCKPositive Net Change

Dental Market Shows Strength Despite Pandemic: 3 Stocks to Watch

by Trina Mukherjee Published on April 15,2021

Let's keep a watch on three lucrative stocks, XRAY, MCK and MMSI, in the dental space that have performed impressively despite the pandemic-led volatility.

medical

Why McKesson (MCK) Could Beat Earnings Estimates Again

by Zacks Equity Research Published on April 13,2021

McKesson (MCK) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

MCKPositive Net Change

Here's Why You Should Hold on to McKesson (MCK) Stock Now

by Zacks Equity Research Published on April 12,2021

McKesson (MCK) continues to benefit from multi-year strategic growth initiative and Distribution Solutions segment.

Quest Diagnostics (DGX) Divests Minority Share of Q2 Solutions

by Zacks Equity Research Published on April 05,2021

Quest Diagnostics' (DGX) divestment of Q2 solutions to IQVIA will allow IQVIA to lead Q2 Solutions on the next stage of its journey in central lab services as a global leader.

medical

The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Hill-Rom Holdings, Owens & Minor, McKesson Corp and Meridian Bioscience

by Zacks Equity Research Published on April 05,2021

The Zacks Analyst Blog Highlights: Becton, Dickinson and Co, Hill-Rom Holdings, Owens & Minor, McKesson Corp and Meridian Bioscience

medical

4 Lucrative MedTech Stocks to Bet On in 2021 Amid Pandemic

by Trina Mukherjee Published on April 01,2021

Grab these four top stocks, HRC, OMI, MCK and VIVO, which continue to show promise amid the pandemic and can turn out to be wise investment choices for 2021.